Predict your next investment

Actinobac Biomed company logo
HEALTHCARE | Drug Development
actinobac.com

See what CB Insights has to offer

Stage

Unattributed VC | Alive

Total Raised

$5.1M

Last Raised

$1M | 3 yrs ago

About Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Actinobac Biomed Headquarter Location

15 Pelham Road

Kendall Park, New Jersey, 08824,

United States

732-371-2694

Latest Actinobac Biomed News

Dental School Researcher Gets Approval To Begin Clinical Trials For Cancer Therapy

May 26, 2021

Treatment Uses Protein found in Oral Bacterium Scott Kachlany Newswise — A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany’s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. The approval clears the way for Kachlany’s company, Actinobac Biomed, to initiate a phase I clinical trial in patients who have relapsed or refractory leukemia or lymphoma. Their experimental drug, Leukothera, has additionally proven effective in treating autoimmune diseases in animals, and Actinobac is also developing its use for that purpose. Unlike many treatments for cancer, Leukothera rapidly kills cancer cells but does not compromise the immune system. “Doctors and patients often have to trade efficacy for safety. However, we hope to provide patients with a treatment option that has both a strong safety profile and robust efficacy,” said Kachlany, a professor in the dental school’s Department of Oral Biology and Actinobac’s chief scientist. Clinical trials for Leukothera will begin with 24 patients but could be expanded to include an additional cohort of 20 patients or more if the response is positive, said Kachlany, who has been working on the treatment for nearly a decade. Because patients will receive Leukothera for a short time span of once a week for four weeks, he expects to gather data quickly. If Leukothera is effective, with minimal or no negative side effects, patients can continue “compassionate care” treatment, said Kachlany. The first phase of trials, which will take approximately two years to complete, will focus primarily on safety. The trial will be conducted at three sites, including Rutgers Cancer Institute of New Jersey. In the near future, Actionobac could also begin testing Leukothera in patients with other diseases such as inflammatory bowel disease, Kachlany said. Actinobac has been funded by the NIH, the New Jersey Health Foundation, and Kairos Ventures. Request an Expert

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Actinobac Biomed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Actinobac Biomed is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

E

Eye Health

711 items

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,330 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Actinobac Biomed Patents

Actinobac Biomed has filed 7 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Immunology
  • HIV/AIDS
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/6/2020

5/4/2021

Hepatotoxins, Autoimmune diseases, Bacterial toxins, Immunology, HIV/AIDS

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/6/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/4/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Hepatotoxins, Autoimmune diseases, Bacterial toxins, Immunology, HIV/AIDS

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.